Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

Teva Pharmaceuticals has launched the first generic GLP-1 drug for weight loss in adults and adolescents; a lower-cost ...

Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a ...

The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda.

The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) said its U.S. affiliate announced today the FDA approval and U.S. launch of a generic version of Saxenda®1 (liraglutide injection). “With this approval ...

More than 1.1 million prescriptions for the weight-loss drugs Saxenda and Wegovy have been issued in South Korea over the ...